Catalytic ROS‐Amplifying Self‐Immolative Linkers Enable Carrier‐Free Prodrugs for Refractory Tumors
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.8965077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Qiwei Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Discovery, State Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Prodrugs, Reactive Oxygen Species, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Science Foundation for Young Scientists of China, State Key Laboratory of Natural Medicines.
Abstract (Originalsprache)
Redox‐buffering systems in tumors heighten chemoresistance, yet most ROS‐responsive linkers used in prodrug design consume oxidants, exhibit limited sensitivity to endogenous ROS, and often require external triggers or complex formulations, constraining clinical translation. Here we report a phenylselanyl cyclohexenone self‐immolative linker that couples ROS‐triggered cleavage with organoselenium‐mediated redox amplification within a single small‐molecule architecture. Oxidation of the selanyl group generates a selenoxide that undergoes aromatization‐assisted β‐elimination followed by 1,6‐self‐elimination, releasing the payload together with a redox‐active selenium species. The released selenium species is proposed to engage in a GSH‐dependent redox cycle that increases intracellular oxidative burden, thereby reinforcing ROS‐triggered activation and weakening antioxidant buffering. This modular motif enables the construction of carrier‐free prodrugs spanning chemotherapeutics and small‐molecule inhibitors. These prodrugs remain stable in neutral media yet are efficiently activated by endogenous ROS, achieving improved biodistribution, reduced systemic toxicity, and enhanced antitumor activity across breast cancer, pancreatic ductal adenocarcinoma, and patient‐derived leukemia models. By coupling selective activation with catalytic redox amplification, this ROS‐amplifying self‐immolative linker provides a modular strategy for overcoming redox‐associated drug resistance and for advancing the translational potential of small‐molecule prodrugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Drug Discovery, State Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing, China.
- China Pancreas Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
- Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
- Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pha…
ORCID-Profile: Wei Zhang, Yueqin Zheng
Förderung
- National Natural Science Foundation of China
- National Science Foundation for Young Scientists of China
- State Key Laboratory of Natural Medicines
- Lingang Laboratory
Zitieren
APA
Zhou, Q., Wang, Y., Han, Y., Zhang, W., Ban, C., Hao, Z., Li, W., Wang, Y., Du, C., Liang, Y., Jia, N., Zhou, Y., Guo, W., & Zheng, Y. (2026). Catalytic ROS‐Amplifying Self‐Immolative Linkers Enable Carrier‐Free Prodrugs for Refractory Tumors. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.8965077
Vancouver
Zhou Q, Wang Y, Han Y, Zhang W, Ban C, Hao Z, et al. Catalytic ROS‐Amplifying Self‐Immolative Linkers Enable Carrier‐Free Prodrugs for Refractory Tumors. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.8965077
BibTeX
@article{Zhou2026,
author = {Zhou, Qiwei and Wang, Yazhou and Han, Yulin and Zhang, Wei and Ban, Chao and Hao, Ziteng and Li, Wei and Wang, Yuanan and Du, Changling and Liang, Yan and Jia, Nan and Zhou, Yue and Guo, Weiwei and Zheng, Yueqin},
title = {Catalytic ROS‐Amplifying Self‐Immolative Linkers Enable Carrier‐Free Prodrugs for Refractory Tumors},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.8965077}
}
EUVIMED